Skip to content
E3 · Other / exploratoryReviewPEM unclearNarrative reviewPeer-reviewed
Standard · 3 min

The Long Road of Long COVID: Specific Considerations for the Allergist/Immunologist.

Bellanti, Joseph A, Novak, Peter, Faitelson, Yoram et al.

The journal of allergy and clinical immunology. In practice2023DOIPubMed

Design
Narrative review
Participants
Not reported
PEM required
Unclear
Case definition
Not stated in the abstract

Quick Summary

Long COVID is a condition that develops after a COVID-19 infection and can cause symptoms affecting many parts of the body, including heart problems, blood clots, fatigue, and autoimmune issues. This review examines what causes Long COVID and which patients are most at risk, noting that certain groups like Hispanic and Latino communities face higher rates. The authors highlight that while vaccines help prevent severe acute COVID, we still need more research to understand how they affect Long COVID development and progression.

Why It Matters

This review is important because Long COVID and ME/CFS share overlapping symptoms (fatigue, dysautonomia, cardiac issues, post-exertional malaise) and immune dysfunction, helping researchers understand potential common pathways. Understanding immunological mechanisms in Long COVID may illuminate similar dysregulated immune responses in ME/CFS. The emphasis on inflammatory pathways as drug targets could have direct implications for ME/CFS treatment development.

Observed Findings

What the study reports it measured.

  • Long COVID presents with multisystem involvement including cardiovascular (palpitations, chest pain), thrombotic, metabolic, neurological (dysautonomia), and autoimmune manifestations.
  • Certain populations show higher Long COVID prevalence, including Hispanic and Latino individuals and those with low socioeconomic status.
  • Approximately one-third of Long COVID patients have no identifiable preexisting risk factors or conditions.
  • Epstein-Barr virus reactivation and autoantibodies are documented associations in Long COVID cases.
  • Several inflammatory pathways have been proposed as mechanistic targets for novel therapeutic interventions currently in clinical trials.

Inferred Conclusions

What the authors interpret from those results.

  • Immune dysregulation and inflammatory pathways are central to Long COVID pathogenesis and warrant investigation as therapeutic targets.
  • Immunologists should recognize Long COVID as a multisystem disorder with specific relevance to allergic and immunological mechanisms including autoimmunity and viral reactivation.
  • Disparities in Long COVID prevalence suggest both biological and social factors influence disease risk and outcomes.
  • Further research is needed on vaccination's effects on Long COVID development, as current evidence is insufficient to draw conclusions.

Remaining Questions

  • What is the specific role of vaccination in preventing or modifying Long COVID development and severity?
  • Which inflammatory pathways are most important for different Long COVID symptom clusters, and can they be targeted therapeutically?
  • Why do approximately one-third of Long COVID patients lack identifiable risk factors, and what mechanisms explain disease development in this group?
  • How do immunological findings in Long COVID relate to ME/CFS pathophysiology, and are there shared therapeutic approaches?

What This Study Does Not Prove

This review does not establish causation for any Long COVID symptoms or prove that specific inflammatory pathways directly cause the condition—it identifies associations and proposed mechanisms under investigation. The review cannot determine whether vaccination modifies Long COVID risk since the authors explicitly note limited data on this question. Being a narrative review rather than a meta-analysis, it does not quantify effect sizes or provide systematic evidence synthesis.

Explore further

About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →

Cite this study

The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.

Primary citation

Bellanti, Joseph A, Novak, Peter, Faitelson, Yoram, Bernstein, Jonathan A, & Castells, Mariana C (2023). The Long Road of Long COVID: Specific Considerations for the Allergist/Immunologist.. The journal of allergy and clinical immunology. In practice. https://doi.org/10.1016/j.jaip.2023.09.014

BibTeX

@article{mecfsatlas-bellanti-2023-long-road,
  author  = {Bellanti, Joseph A and Novak, Peter and Faitelson, Yoram and Bernstein, Jonathan A and Castells, Mariana C},
  title   = {The Long Road of Long COVID: Specific Considerations for the Allergist/Immunologist.},
  journal = {The journal of allergy and clinical immunology. In practice},
  year    = {2023},
  doi     = {10.1016/j.jaip.2023.09.014},
  note    = {PubMed: 37774781},
  url     = {https://www.mecfsatlas.com/evidence/bellanti-2023-long-road},
}

Atlas snapshot reference

ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/bellanti-2023-long-road

Contribute

Private, reviewed by a human. Not a public comment thread.